Cargando…
Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate
Hyperphosphatemia is an inevitable consequence of end stage chronic kidney disease and is present in the majority of dialysis patients. Recent observational data has associated hyperphosphatemia with increased cardiovascular mortality among dialysis patients. Dietary restriction of phosphate and cur...
Autores principales: | Mohammed, Ismail A, Hutchison, Alastair J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621404/ https://www.ncbi.nlm.nih.gov/pubmed/19209270 |
Ejemplares similares
-
Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden
por: Hutchison, Alastair J., et al.
Publicado: (2008) -
Lanthanum carbonate: safety data after 10 years
por: Hutchison, Alastair J, et al.
Publicado: (2016) -
Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients
por: Hutchison, Alastair J, et al.
Publicado: (2013) -
Pharmacology of the Phosphate Binder, Lanthanum Carbonate
por: Damment, Stephen JP
Publicado: (2011) -
Encephalopathy in a dialysis patient treated with lanthanum carbonate (LC)
por: Brancaccio, Diego, et al.
Publicado: (2012)